Comparison
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676 vs 3q26 Microduplication Syndrome C4755319
Clinical comparison between 6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency and 3q26 Microduplication Syndrome for differential diagnosis and treatment planning.
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
A metabolic disorder affecting neurotransmitter production, caused by deficiency of a specific enzyme. Requires careful dietary management and medication.
3q26 Microduplication Syndrome C4755319
A genetic condition involving extra genetic material at chromosome 3q26, which can cause developmental delays and other features depending on specific genes involved.
6 comparison axes
Onset
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
0-1
3q26 Microduplication Syndrome C4755319
0-null
Onset patterns differ
Severity
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
severe
3q26 Microduplication Syndrome C4755319
moderate
Different severity levels
Chronic
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
Chronic
3q26 Microduplication Syndrome C4755319
Chronic
Differing course
Communicable
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
No
3q26 Microduplication Syndrome C4755319
No
Different transmission
Body System
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
metabolic
3q26 Microduplication Syndrome C4755319
congenital
Same/different system
Category
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
metabolic
3q26 Microduplication Syndrome C4755319
genetic
Different category
Bottom line
6-pyruvoyl-tetrahydrobiopterin-synthase-deficiency-C0878676 and 3q26-microduplication-syndrome-C4755319 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676 | 3q26 Microduplication Syndrome C4755319 | Discriminating power |
|---|---|---|---|
| Mechanism | Enzyme deficiency affecting neurotransmitter-related metabolism | Extra genetic material at chromosome 3q26 | High |
| Onset | Typically considered in infancy, age 0–1 | Congenital; age at recognition may vary | Moderate |
| Clinical pattern | Severe metabolic disorder needing diet and medication oversight | Developmental delay and other features vary by genes involved | Moderate |
When to favor each condition
Choose 6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676 when
Suspected inherited metabolic disease in infancy
The supplied category and enzyme mechanism fit PTPS deficiency
High
Abnormal metabolic or neurotransmitter-related testing
This may support consideration, but a result alone is not a diagnosis
Moderate
Need for metabolic treatment supervision
The description specifies careful dietary management and medication
Moderate
Choose 3q26 Microduplication Syndrome C4755319 when
Developmental concerns suggesting a copy-number disorder
3q26 microduplication is a congenital genomic condition
High
Microarray shows extra material at 3q26
This finding directs evaluation, with gene content determining relevance
High
No primary metabolic explanation
A chromosomal syndrome may better fit variable congenital features
Moderate
How key tests differ
| Test | 6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676 | 3q26 Microduplication Syndrome C4755319 | Interpretation |
|---|---|---|---|
| Metabolic or neurotransmitter testing | May be abnormal; no cutoff is established here | No defining metabolic abnormality is established | Abnormal results require specialist confirmation |
| PTPS gene or enzyme assessment | Pathogenic variant or deficient activity can support diagnosis | Not the defining test | Confirmation should be clinician-directed |
| Chromosomal microarray | Not expected to define the enzyme disorder | May detect extra 3q26 material | Size, genes, and clinical correlation determine significance |
Prognosis comparison
6 Pyruvoyl Tetrahydrobiopterin Synthase Deficiency C0878676
- Outcome
- Chronic severe disorder; exact outcome is not established
- Factors
- Recognition, metabolic control, and neurologic involvement may matter
3q26 Microduplication Syndrome C4755319
- Outcome
- Chronic congenital condition with variable moderate effects
- Factors
- Duplication size, involved genes, and support needs
Time frame: Lifelong; infancy is especially relevant for the metabolic disorder
Individual prognosis requires clinician interpretation; mortality data are not supplied
Complications comparison
| Complication | Presentation |
|---|---|
| Neurodevelopment | Severe metabolic effects may affect neurologic function Developmental delay is described, with variable severity Exact complications are not established by the supplied data |
| Care burden | Ongoing diet and medication oversight may be required Supportive, individualized care is expected No doses or treatment protocols are provided |
| Associated features | Not primarily a chromosomal malformation syndrome Features depend on duplicated genes and are not uniform Gene content needs clinical review |
Patient education highlights
- HighDifferent conditions
One is a noncontagious metabolic enzyme disorder; the other is a chromosomal microduplication.
- HighTest limitations
An abnormal result does not by itself establish either diagnosis.
- MediumFollow-up
Ask about genetics referral and metabolic or developmental support as appropriate.